Overview of Primosiston

Property	Description
Active Ingredient	Norethisterone acetate and Ethinylestradiol
Form	Oral Tablet or Intramuscular Oil Solution
Pharmacological Class	Estrogen and Progestogen Combination
General Purpose	Acute Hormonal Stabilization
Origin	Synthetic Formulation

What Type of Medicine is Primosiston?

Primosiston is classified as a synthetic combination hormonal preparation and an endocrine agent belonging to the sex hormone analogue pharmacological class. It is a prescription-only medicine (Rx) designed for acute, short-term hormonal intervention. This dual-component medicine is potent, achieving its therapeutic effect by mimicking and significantly amplifying the influence of the body's natural sex hormones, progestogen and estrogen. The drug's rapid-acting profile is clinically recognized for its effectiveness in providing immediate hormonal support.

Composition and Formulation: Synthetic Estrogen and Progestogen

Primosiston's active ingredients are entirely synthetic in origin. The most common formulation features the progestogen Norethisterone acetate combined with the estrogen Ethinylestradiol. This high-concentration composition is one of its differentiating features, as it allows for the swift delivery of the required hormonal load. While typically supplied as an oral tablet, an oil solution intended for intramuscular administration exists, which may contain Estradiol benzoate and Hydroxyprogesterone caproate in certain regional or historical forms.

General Purpose: Acute Hormonal Stabilization

The primary general purpose of Primosiston is to provide acute hormonal stabilization to quickly control certain types of abnormal uterine bleeding, such as a sudden, heavy bleeding event. Its function is centered on inducing rapid endometrial stabilization; the high hormonal concentration swiftly reinforces and consolidates the uterine lining. This prompt action makes the medicine an effective antihemorrhagic agent intended for the swift cessation or significant reduction of excessive, non-standard blood loss. The goal of the intervention is strictly temporary control, enabling the patient's own physiological mechanisms to eventually resume normal menstrual cycle regulation.

Regulatory References

What side effects are possible with Primosiston?

Possible side effects and safety information

The official safety profile for the combination of Norethisterone acetate and Ethinylestradiol is structured around classifying adverse reactions by frequency and physiological system. Common adverse reactions (incidence ge 2%) documented in regulatory sources typically include headache, nausea, vomiting, abdominal pain, and breast tenderness, as well as weight fluctuation and mood changes.

Serious Adverse Reactions and Systemic Risks

The most serious documented safety concerns, which carry a risk of morbidity, are associated with the Vascular and Hepatobiliary systems. These include the documented risks of Venous Thromboembolism (such as Deep Vein Thrombosis and Pulmonary Embolism) and Arterial Thromboembolism (such as Stroke and Myocardial Infarction). The development of Hepatic Neoplasia (benign liver tumors) is also listed in regulatory labeling.

Time-Related Patterns and Restrictions

Official documents note that the risk of Venous Thromboembolism is highest during the first year of use or when treatment is restarted after a break of four weeks or more. Safety restrictions (contraindications) prohibit use in individuals with a history of or current thromboembolic disorders, cerebral vascular disease, hormone-sensitive malignancy (e.g., breast cancer), or severe hepatic impairment. Furthermore, the risk of serious cardiovascular events is explicitly noted to be highest in women over 35 years of age who smoke.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is derived exclusively from authoritative government regulatory sources detailing the documented overdose profile of the combined hormonal preparation, Primosiston (Norethisterone acetate and Ethinylestradiol).

Overdose scope	Feature	Official Regulatory Statement
Documented overdose presentations	The most frequently documented acute clinical signs following ingestion of high doses include nausea, vomiting, breast tenderness, and drowsiness.
Physiological systems affected	Acute effects primarily involve the gastrointestinal system and the reproductive system, often resulting in withdrawal bleeding in females.
Population-specific overdose notes	Acute overdose in prepubescent girls may result in vaginal bleeding as a specific clinical manifestation.
Emergency-response statements	Management is strictly symptomatic and supportive; no specific antidote is known.
When immediate medical help is required	Regulatory documents mandate that an individual seek immediate medical attention or contact a poison control center for any suspected overdose event.

Overdose classifications (high-level)	Classification	Official Regulatory Statement
Severity classification	Acute, high-dose ingestion is characterized by low acute toxicity and serious adverse effects are considered unlikely.
Overdose-context constraints	Close clinical observation is required, and hospital monitoring may be necessary depending on the quantity ingested and the patient's clinical status.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by stating that, despite symptoms being generally mild, all suspected overdose events mandate immediate medical evaluation. This regulatory instruction is based on the need for professional observation and the provision of symptomatic treatment, as no specific antidote is available for the active components.

Therapeutic Uses of Primosiston

What Primosiston Treats: Main Uses and Benefits

The medication is applied in addressing conditions marked by temporary physiological imbalance related to the female reproductive system. The component hormones are relevant for the treatment of menstrual bleeding irregularities.

Management of Acute, Excessive Uterine Bleeding

Primosiston is commonly used across conditions presenting with acute episodes of excessive uterine blood loss and irregular bleeding patterns (Dysfunctional Uterine Bleeding). The medication is used to help manage the flow and duration of acute, unscheduled episodes. This provides supportive relief that helps ease the overall symptom burden by assisting with the management of bleeding. It is commonly used to help with symptoms stemming from Dysfunctional Uterine Bleeding and is relevant for easing symptoms that interfere with daily functioning, such as those related to situational cycle timing.

“The benefit contributes to improved comfort by providing supportive relief that helps patients cope more steadily during difficult episodes of heavy, unscheduled bleeding.”

Situational Support and Short-Term Cycle Management

The medication is relevant in clinical settings that involve temporary management of the menstrual cycle. It is often applied during phases when symptoms become more noticeable following the control of an acute bleeding crisis, supporting the patient during difficult episodes by easing distress. The benefit helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Excessive Uterine Blood Loss and Situational Cycle Timing

Eligibility and Restrictions for Use

Who Can and Cannot Use Primosiston?

The eligibility profile for Primosiston (Norethisterone acetate and Ethinylestradiol) is strictly defined by regulatory authorities based on risks associated with potent combined hormonal preparations. The medicine is absolutely contraindicated in several populations.

Contraindicated Populations (Must Not Use)

Contraindication Category	Examples of Non-Eligibility
Thrombotic Risk	Current or history of deep vein thrombosis, pulmonary embolism, stroke, or heart attack.
Hormone-Sensitive Disease	Current or history of breast cancer or other known estrogen-dependent malignant tumors.
Hepatic Function	Active severe liver disease or the presence of hepatic tumors (adenomas/carcinomas).
High-Risk Profile	Women who smoke and are over 35 years of age.
Reproductive Status	Known or suspected pregnancy; generally not recommended while breastfeeding.

Age and Condition Limitations

Primosiston use is not established in the pediatric population (children and adolescents) and older adults (women over 65). The medicine must also not be used in cases of undiagnosed abnormal genital bleeding, migraine with aura, or in patients with certain thrombophilic disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The official regulatory profile for Primosiston primarily addresses pharmacokinetic interactions that alter the systemic exposure of its hormonal components. Medicinal product categories with documented interactions include CYP3A4 Enzyme Inducers, certain Anticonvulsants, Antibiotics, and specific Hepatitis C combination therapies.

Formal Restrictions and Metabolic Effects

Co-administration with drug regimens containing Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir, is formally prohibited due to the documented risk of significant liver enzyme elevation. This is classified as a contraindicated combination.

The most common mechanistic basis for other interactions is Cytochrome P450 3A4 (CYP3A4) induction. Substances like Rifampicin, Phenytoin, or the herbal product St. John's Wort are documented as inducers that accelerate hormone clearance, thereby reducing the systemic concentration of Norethisterone and Ethinylestradiol.

Conversely, some substances, including Ascorbic Acid and Acetaminophen, are documented to increase Ethinylestradiol plasma concentrations by inhibiting clearance pathways. The estrogen component itself is known to induce the clearance of other medicines, notably Lamotrigine, by promoting its glucuronidation. No mandatory timing or separation rules are listed for dose co-administration. Population-specific interaction notes confirm that altered clearance leading to higher exposure may occur in patients with hepatic impairment or chronic renal failure.

Mechanism of Action

How Primosiston Works

The mechanism involves the coordinated action of its synthetic components, Norethisterone acetate and Ethinylestradiol, which function as agonists on the Progesterone (PR) and Estrogen (ER) Receptors, respectively. This high-concentration hormonal load exerts negative feedback inhibition on the Hypothalamic-Pituitary-Ovarian (HPO) axis, the body's central cycle regulator. This action rapidly suppresses the release of FSH and LH, resulting in the reduction of endogenous ovarian stimulus.

The most significant localized physiological modulation occurs in the uterus. The Norethisterone acetate component forces a rapid and profound process of decidualization, converting the shedding uterine lining into a dense, structurally consolidated secretory tissue. Concurrently, this high progestogenic action promotes vasoconstriction and support of the small spiral arterioles within the tissue. This combined tissue conversion and local vascular control provides a physiological mechanism that promotes the physical cohesion of the uterine lining.

Crucially, the Ethinylestradiol component acts synergistically to upregulate the concentration and sensitivity of the Progesterone Receptors in the endometrium. This estrogen priming facilitates a more complete and rapid structural conversion by the Norethisterone acetate, influencing the kinetics of the mechanism's overall effect profile.

Dosage and Administration Information

Primosiston is an oral medication utilized for short-term hormonal stabilization, with established dosing regimens based on the Norethisterone 5 mg tablet strength. The usage is defined by two primary patterns: a rapid acute course and a subsequent cyclic regimen.

For the management of acute, excessive uterine bleeding, the standard regimen involves taking one 5 mg tablet three times daily (TID). This high-frequency pattern is utilized for a fixed, short course of 10 days to ensure the rapid establishment of hormonal stabilization. The tablets must be swallowed whole with liquid and are not to be crushed or altered. A key procedural rule for this course is that the intake must not be interrupted or stopped before the full 10-day duration is completed, even if slight bleeding occurs after initial cessation. Following the final dose of the acute course, withdrawal bleeding, resembling a menstrual period, is generally expected to begin within 2 to 4 days.

For the purpose of preventing the recurrence of irregular bleeding, the established usage shifts to a lower-dose, cyclic pattern. The typical dose is one 5 mg tablet taken once or twice daily, administered on specific days of the menstrual cycle, such as Day 16 to Day 25. In terms of administration for specific populations, it is specified that the medication is not intended for use in children. If a dose is missed, patients are instructed to take the last missed tablet immediately and continue the subsequent doses at the regularly scheduled time.

Recent Clinical Evidence

Primosiston: Recent Clinical Evidence

Summary of Key Research Findings

Primosiston is a fixed-dose combination of a progestogen ( norethisterone acetate) and an estrogen ( ethinylestradiol). Clinical research and guidelines primarily evaluate its use for the treatment of functional uterine bleeding and for short-term hormonal cycle control. Studies focus on its efficacy in quickly stopping non-organic bleeding and regulating the subsequent menstrual cycle.

The combination aims to stabilize the endometrium, thereby halting bleeding that is not caused by underlying anatomical or pathological issues.
Research emphasizes its appropriate use only after serious organic causes of bleeding have been ruled out by a healthcare professional.

Efficacy and Study Focus

Clinical data suggest that the administration of Primosiston is associated with the cessation of functional bleeding in a high percentage of cases shortly after treatment initiation. One primary outcome evaluated in studies is the time elapsed until the bleeding stops. Research indicates that the progestogen component is key to achieving endometrial stabilization.

Outcome Evaluated	Measure of Success	Population Studied
Control of Uterine Bleeding	Time to bleeding cessation (usually within 1-3 days)	Women with dysfunctional uterine bleeding
Cycle Regulation	Resumption of expected cycle after treatment	Women requiring short-term hormonal support

Safety and Tolerability Profile

As with most hormonal combinations, the safety profile includes common potential adverse events. The most frequently reported side effects in studies include nausea, headache, and breast tenderness. Due to the thrombogenic risk associated with estrogen, the treatment is typically administered for short durations. Research protocols stress that a complete patient history is essential to exclude individuals with known risk factors for thromboembolic events.

Key Studies & References ACOG Practice Bulletin No. 136: Management of Abnormal Uterine Bleeding

Frequently Asked Questions (FAQ)

Common questions about Primosiston (FAQ)

Q: How is Primosiston different from birth control pills in its primary function?

A: Primosiston is classified by regulatory authorities for the specific purpose of acute hormonal stabilization, typically to help stop abnormal uterine bleeding. Unlike birth control pills, which are approved for long-term contraception, this medicine is not approved or intended for use as a contraceptive agent. Its approved dosage regimens are distinct from those used for cycle-long pregnancy prevention.

Q: Is it normal to have spotting or unusual bleeding while taking Primosiston?

A: Official product information indicates that bleeding irregularities, often described as spotting, may be a potential adverse reaction to hormonal preparations. This is considered more likely during the initial phase of treatment as the body adjusts to the high hormonal load. Official guidelines suggest the treatment course should not be interrupted, even if slight bleeding occurs.

Q: What is the expected outcome if Primosiston is taken to delay a menstrual period?

A: When the medicine is administered for the postponement of menstruation, the intended outcome is the temporary deferral of the scheduled withdrawal bleed. The bleed is typically expected to begin after the course of the medication has been completed. This temporary effect is based on the drug's function of providing acute hormonal support to the uterine lining.

Q: Is there a maximum number of cycles or days for which Primosiston is typically prescribed?

A: Regulatory documents emphasize that Primosiston is intended for short-term hormonal intervention due to its potent composition. For acute treatment, a fixed, short course is specified. The medication is not intended for continuous, long-term administration, and the duration of any cyclic use is typically managed on a short-term basis.

Q: Are there specific instructions for stopping Primosiston after a course of treatment?

A: Official guidance states that after the treatment course is finished, a withdrawal bleed is generally expected to occur within two to four days. This bleed resembles a normal menstrual period. If the expected bleeding does not occur or is unusually heavy, professional medical review may be necessary.

Q: What are the signs of a serious interaction that users should be aware of?

A: Serious signs that may signal an adverse interaction often overlap with the drug's most serious risks, such as thromboembolism or hepatic issues. These can manifest as severe leg pain, sudden shortness of breath, unexplained sharp chest pain, or yellowing of the skin or eyes (jaundice). If these signs develop, official guidance emphasizes the need for immediate medical attention.

Q: Can Primosiston be used in pre-menopausal individuals?

A: According to regulatory documents, the medicine is indicated for conditions of abnormal uterine bleeding and cycle regulation, which are problems encountered by women of reproductive age. Use is specifically restricted in pediatric populations, in women over 65 years of age, and during pregnancy.

Q: Is Primosiston used for issues other than period problems?

A: Official therapeutic indications for this medication are limited to conditions related to abnormal uterine bleeding and menstrual cycle control. It is classified as an antihemorrhagic agent intended for short-term hormonal stabilization. The regulatory profile does not include indications for non-menstrual conditions.

Q: What official documents describe the active ingredients in Primosiston?

A: The active ingredients are explicitly listed in several official documents issued by regulatory bodies worldwide. These include the Summary of Product Characteristics (SmPC), the FDA Prescribing Information (or equivalent), and the Patient Information Leaflet (PIL). These documents provide the full chemical names and concentrations of the synthetic hormones.

Q: Are there any dietary restrictions mentioned in the official guidance for Primosiston?

A: Official guidance documents address interactions between the medicine and other substances, including certain foods and beverages. Some hormonal product labels caution against consumption of grapefruit juice due to its potential to affect how the medicine is metabolized by the body.

Q: Why do some official sources refer to Primosiston by its active ingredients instead of the brand name?

A: Regulatory and scientific sources prioritize the use of the International Non-proprietary Name (INN), which refers to the active ingredients. This practice ensures clarity and consistency across medical literature and helps avoid confusion, as the drug may be sold under different brand names in various regions.

Q: Can Primosiston affect the results of routine medical lab tests?

A: Yes, official information for hormonal preparations indicates that they may affect the results of certain laboratory tests. This interference can occur with tests measuring endocrine function, liver function, and blood coagulation markers.

Q: Does Primosiston have a 'black box' warning in regulatory documents, and what does it concern?

A: FDA-regulated labels may include a Boxed Warning, which is a special alert about the drug's most serious potential risks. For this type of combined hormonal medication, the warning typically details the risk of serious cardiovascular events, such as arterial and venous thromboembolism.

Q: Do any official warnings mention Primosiston causing allergic reactions?

A: Official regulatory lists of undesirable effects generally include the potential for hypersensitivity or allergic reactions. These reactions can range from skin rash and hives (urticaria) to more serious swelling (angioedema), and their documented frequency is classified within the safety profile.

Q: Can Primosiston cause issues with vision or eyes?

A: Regulatory documentation for combined hormonal products often includes information about potential ocular disturbances. These may include, but are not limited to, visual impairment, changes in vision, or problems with contact lens tolerance.

Q: Are the side effects of Primosiston temporary, or do they continue after stopping the medication?

A: Regulatory information generally notes that common side effects, such as nausea or breast tenderness, are most frequent during the initial phase of taking the medication. These effects are typically expected to resolve and stop once the course of treatment is officially completed.

Q: Does Primosiston impact blood sugar levels for non-diabetics?

A: Yes, hormonal preparations are known to affect glucose tolerance and carbohydrate metabolism. Official product information contains warnings regarding the potential for changes to blood sugar levels and advises appropriate caution.

Q: What are the official recommendations regarding driving or operating machinery while taking Primosiston?

A: Regulatory documents include a specific section addressing the effects of the medication on the ability to drive and operate machinery. If the drug is known to cause effects that could impair these abilities, such as dizziness or fatigue, this information is explicitly stated.

Q: Is it safe to drink alcohol while taking Primosiston, according to official guidance?

A: Official regulatory documentation will include an explicit statement if a severe or clinically relevant interaction is known between the medication and alcohol. In cases where no hard contraindication exists, patients are generally advised to follow general safety guidelines.

Q: What are the official sources for patient information leaflets (PILs) for Primosiston?

A: The Patient Information Leaflets (PILs) for the medicine are published and made accessible by national and regional medicines regulatory authorities. These official documents can typically be found directly on the government websites of bodies such as the EMA or FDA (DailyMed).

Q: Is it safe to drink grapefruit juice while taking Primosiston?

A: Official regulatory documentation addresses the interaction between the drug and certain foods, including grapefruit juice. Since the drug's components are metabolized by the CYP3A4 enzyme, the label provides guidance on consuming grapefruit juice due to its potential to inhibit this enzyme.

How should Primosiston be stored and disposed of?

Primosiston storage and disposal must strictly follow the requirements documented in official regulatory labeling to ensure product quality and safety.

Official Storage Conditions

Item	Regulatory Requirement
Storage Temperature:	Store at controlled room temperature, typically below 30 C.
Environmental Protection:	Must be protected from light and kept away from excessive moisture.
Handling Constraints:	Do not freeze; keep the product in its original packaging to maintain integrity.
Child Safety:	Mandatory instruction to keep out of the sight and reach of children.

Official Disposal Instructions

For disposal of unused or expired tablets, the official instructions mandate that the medicine must not be thrown away with household trash or disposed of via wastewater (e.g., flushed down a toilet or sink). The product must be disposed of according to local pharmaceutical requirements, often by returning it to a pharmacy or designated collection program. These rules prevent the hormonal components from entering the environment.

Primosiston